SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons quarterly results sparked debate as strong AWS growth was overshadowed by heavy AI infrastructure spending and worsening free-cash-flow concerns, contributing to pressure on the shares and broader tech sentiment. Traders are split between worries about when the spending will pay off and dip buyers who see resilient cloud demand and point to the stocks sharp rebound.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs REGAL Phase 3 trial reaching its 80-event threshold has shifted attention to the upcoming GPS survival-data readout after database lock and final analysis. Traders are sharply divided: bulls expect a meaningful survival benefit, while skeptics question the trials dosing changes, control-arm outcomes and whether the results will support approval.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovins steep selloff ahead of its upcoming earnings report is driving attention, with traders weighing concerns about advertising demand, competition and weakness across ad-tech and software stocks. Bulls argue the decline has outpaced the companys fundamentals and are buying the dip, while bears fear the report or outlook could validate further downside.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs upcoming Q3 earnings report is the main focus, with traders looking beyond a potential beat to whether guidance can sustain its AI growth story amid a broader pullback in tech stocks. Bulls expect strong results and a raised outlook, while bears argue the valuation leaves little room for an ordinary quarter or disappointing guidance.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA accelerated approval of Voceryq, a competing treatment for recurrent respiratory papillomatosis, has raised concerns about competition for Precigens Papzimeos. Traders debate whether Voceryqs surgery-free dosing will erode demand or whether Papzimeos can retain an advantage through its commercial head start, established payer access, and full approval.

Invesco DB US Dollar Index Bullish Fund - Invesco DB US Dollar Index Bullish Fund

Invesco DB US Dollar Index Bullish Fund

Shifting expectations for Fed policy and U.S. interest rates are driving discussion of the dollars moves against major currencies. Traders are split between seeing higher yields and rate-hike bets as support for UUP and warning that fiscal concerns and dollar weakness could undermine the trend.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPals Q3 results are driving attention: adjusted earnings beat expectations and full-year guidance rose, while revenue missed and growth remained modest. Traders are split between viewing cash flow and buybacks as support and worrying that weak branded-checkout growth and margin pressure undermine the turnaround; takeover and bank-charter chatter remains speculative.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPaths post-earnings selloff and analyst downgrades following its Investor Day are driving discussion, with traders focused on skepticism about slowing growth and whether its agentic-AI push can translate into stronger revenue. Bulls view the companys orchestration products, cash position, and enterprise potential as undervalued, while bears say the business still needs to prove the strategy commercially.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

A third-party photo and commentary identifying POET hardware in Foxconns photonics ecosystem has renewed attention to the FIT collaboration, with traders treating it as validation while debating whether it could lead to production orders; POET has not confirmed new orders. Traders are also weighing reported MarvellLumentum acquisition talks, speculating that optics-sector consolidation could benefit POET as an independent supplier, though others see potential competitive or supply-chain risks.

Nasdaq, Inc. is a holding company, which engages in trading, clearing, exchange technology, regulatory, securities listing, information, and public and private company services. It operates through the following segments: Capital Access Platforms, Financial Technology, and Market Services. The Capital Access Platforms segment delivers liquidity, transparency, and integrity to the corporate issuer and investment community by empowering clients to effectively navigate the capital markets, achieve their sustainability goals, and drive governance excellence. The Financial Technology segment offers platforms that improve the liquidity, transparency, and integrity of the global economy by architecting and operating the markets. The Market Services segment includes equity derivative trading and clearing, cash equity trading, fixed income, currency, and commodities trading. The company was founded by Gordon S. Macklin in 1971 and is headquartered in New York, NY.

Nasdaq Inc

Nasdaqs Q3 results are drawing attention, with traders highlighting growth in recurring revenue and index-related business. The upbeat results are tempered by concerns about softer IPO activity and slowing market-services growth, alongside broader weakness in tech stocks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ABCL 

$ABCL
 AbCellera’s moat isn’t generic “AI drug discovery.” It’s proprietary high-throughput microfluidic single-cell screening of natural immune repertoires + deep expertise on hard targets (GPCRs/ion channels) + end-to-end infrastructure (including own clinical manufacturing). AI is layered on top of that stack—not the stack itself.
Anthropic’s wet lab + models are early and powerful on design/ops, but don’t replicate a decade of specialized wet-lab hardware, proprietary data, and clinical assets like ABCL635. The computational layer is what is probably getting commoditized with big players like Anthropic entering this space with a wetlab as well but they don’t have integrated biology platform. Well, unless they acquire Abcellera of course for $100 a share 😀

Stonk Trades

TopOptionsAlerts®

StockTwits for iOS

AbCellera Biologics Inc


 AbCellera’s moat isn’t generic “AI drug discovery.” It’s proprietary high-throughput microfluidic single-cell screening of natural immune repertoires + deep expertise on hard targets (GPCRs/ion channels) + end-to-end infrastructure (including own clinical manufacturing). AI is layered on top of that stack—not the stack itself.
Anthropic’s wet lab + models are early and powerful on design/ops, but don’t replicate a decade of specialized wet-lab hardware, proprietary data, and clinical assets like ABCL635. The computational layer is what is probably getting commoditized with big players like Anthropic entering this space with a wetlab as well but they don’t have integrated biology platform. Well, unless they acquire Abcellera of course for $100 a share 😀